CClinicalTrials.gg
Sign In
Not yet recruitingNCT06223581Updated Jan 25, 2024

Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma

An observational study in Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Evaluation of cardiac burden in patients with sever bronchial asthma

Read the detailed description

Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades (1).

  1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.
  2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia.
02

Conditions studied

  • Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma

Browse trials for

03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's planned enrollment of 30 is below the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades .

  1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.
  2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia.3-3-Heart diseases are the most common cause of

Inclusion criteria

  • Patients accepted to be involved in the study.
  • Patients >18 years old .

Exclusion criteria

Exclusion Criteria:

  • severe bronchial asthma patients who have other comorbidities as (chronic chest disease as COPD,ILD, bronchiectasis , , diabetic ,hypertensive ,mechanical ventilated patients, tracheostomized patients, ......)
  • patients \<18 years old . patients refuse to be involved in the study .
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • OtherECHO in sever asthma patient

    Evaluation of cardiac burden in patients with sever bronchial asthma

06

What researchers measure

Primary outcomes

  1. To Evaluation of cardiac burden in patients with sever bronchial asthma

    For Early detection and avoidance of cardiac effects in severe asthma patients

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06223581
Lead sponsor
Assiut University
Responsible party
Ahmad Hany Anwer Ahmed (Principal investigator, Assiut University) — Principal investigator
First posted
Jan 25, 2024
Start date
Jan 17, 2024 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Jan 25, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma→

Other studies from this sponsor

Assiut University

Start the discussion